<?xml version="1.0" ?>
<document id="f8243fd9214e2e45a222a43aad977d882f17e1e9">
  <chunk id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c0" text="Computational analysis and determination of a highly conserved surface exposed segment in H5N1 avian flu and H1N1 swine flu neuraminidase">
    <entity charOffset="95-104" id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c0.e0" ontology_id="DOID_4492" text="avian flu" type="disease"/>
    <entity charOffset="101-104" id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c0.e1" ontology_id="DOID_8469" text="flu" type="disease"/>
    <entity charOffset="120-123" id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c0.e2" ontology_id="DOID_8469" text="flu" type="disease"/>
  </chunk>
  <chunk id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1" text="Background: Catalytic activity of influenza neuraminidase (NA) facilitates elution of progeny virions from infected cells and prevents their self-aggregation mediated by the catalytic site located in the body region. Research on the active site of the molecule has led to development of effective inhibitors like oseltamivir, zanamivir etc, but the high rate of mutation and interspecies reassortment in viral sequences and the recent reports of oseltamivir resistant strains underlines the importance of determining additional target sites for developing future antiviral compounds. In a recent computational study of 173 H5N1 NA gene sequences we had identified a 50-base highly conserved region in 3'-terminal end of the NA gene.">
    <entity charOffset="34-43" id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e0" ontology_id="DOID_8469" text="influenza" type="disease"/>
    <entity charOffset="252-260" id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e1" ontology_id="CHEBI_25367" text="molecule" type="chemical"/>
    <entity charOffset="297-307" id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e2" ontology_id="CHEBI_35222" text="inhibitors" type="chemical"/>
    <entity charOffset="313-324" id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e3" ontology_id="CHEBI_7798" text="oseltamivir" type="chemical"/>
    <entity charOffset="326-335" id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e4" ontology_id="CHEBI_50663" text="zanamivir" type="chemical"/>
    <entity charOffset="446-457" id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e5" ontology_id="CHEBI_7798" text="oseltamivir" type="chemical"/>
    <entity charOffset="563-572" id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e6" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <pair e1="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e0" e2="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e1" id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.p0" relation="true"/>
    <pair e1="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e0" e2="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e2" id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.p1" relation="true"/>
    <pair e1="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e0" e2="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e3" id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.p2" relation="true"/>
    <pair e1="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e0" e2="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e4" id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.p3" relation="true"/>
    <pair e1="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e0" e2="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e5" id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.p4" relation="true"/>
    <pair e1="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e0" e2="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.e6" id="f8243fd9214e2e45a222a43aad977d882f17e1e9.c1.p5" relation="true"/>
  </chunk>
</document>
